Emerging treatments
Tumor necrosis factor (TNF)-alpha inhibitors
There is emerging evidence supporting the use of TNF-alpha inhibitors (e.g., adalimumab) for early-stage Dupuytren disease. One randomized, double-blind, placebo-controlled trial on a UK cohort found that the use of intranodular adalimumab injections were effective in softening and reducing the size of nodules.[63]
Use of this content is subject to our disclaimer